Product Description
Rifamycins are a class of antibiotics that were first discovered in 1957 and are known for their use in treating tuberculosis (TB). Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP); however, resistance is prevalent and the mechanisms range from primary target modification and antibiotic inactivation to cytoplasmic exclusion. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34400805/)
Mechanisms of Action: RNA polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Bangladesh | Belgium | Brazil | Bulgaria | Colombia | Ecuador | Finland | France | Germany | Greece | Hungary | Italy | Lebanon | Luxembourg | Mexico | Morocco | New Zealand | Pakistan | Peru | Poland | Portugal | Russia | Spain | Sweden | Taiwan | Tunisia | Turkey | Ukraine | United States | Venezuela | Vietnam
Approved Indications: Escherichia coli Infections | Diarrhea
Known Adverse Events: Headache | Constipation
Company: Cosmo Technologies
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Estonia, Hungary, Latvia, Lithuania, Poland, Romania
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Colitis, Ulcerative|Diarrhea|Dysentery
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CB-01-11/29 | P2 |
Not yet recruiting |
Dysentery|Diarrhea |
2025-06-01 |
24% |
| CB-01-35/01 | P2 |
Unknown Status |
Colitis, Ulcerative |
2025-05-31 |
|
| CB-01-11/30 | P2 |
Not yet recruiting |
Dysentery|Diarrhea |
2025-01-01 |
24% |